COST-EFFECTIVENESS OF ETANERCEPT AND EFALIZUMAB IN THE MANAGEMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS

被引：0
|
作者：
Ortonne, J. P. [1 ]
Feneron, D. [2 ]
Daures, J. P. [3 ]
Ollivier, A. L. [4 ]
Thiriet, C. [4 ]
Maurel, F. [2 ]
Le Pen, C. [5 ]
机构：
[1] Hop Archet 2, Nice, France
[2] IMS Hlth, Puteaux La Defense, France
[3] CHU Nimes, Nimes, France
[4] Wyeth Pharmaceut, Paris, France
[5] Univ Paris 09, Paris, France
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67017-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A617 / A617
页数：1
相关论文
共 50 条
  • [41] Safety update of etanercept treatment for moderate to severe plaque psoriasis
    Campanati, Anna
    Diotallevi, Federico
    Martina, Emanuela
    Paolinelli, Matteo
    Radi, Giulia
    Offidani, Annamaria
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (04) : 439 - 448
  • [42] Cost per treated patient for etanercept and ustekinumab in patients treated for moderate to severe plaque psoriasis
    Shah, Neel
    Harrison, David
    Wu, Ning
    Lee, Yuan-Chi
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB166 - AB166
  • [43] Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis
    Ferrandiz, C.
    Garcia, A.
    Blasco, A. J.
    Lazaro, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2012, 26 (06) : 768 - 777
  • [44] Efalizumab: Integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis
    Lynde, Charles
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2005, 9 : 1 - 3
  • [45] COST-EFFECTIVENESS OF BIOLOGIC THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN GERMANY
    Betts, K.
    Yan, Y.
    Sundaram, M.
    Hengst, N.
    Wolff, M.
    Bensimon, A. G.
    VALUE IN HEALTH, 2012, 15 (07) : A570 - A570
  • [46] Cost-Effectiveness of Biological Therapy in the Remission Induction of moderate and severe Psoriasis
    Radtke, M. A.
    Schmitt-Rau, K. H.
    Rosenbach, T.
    Augustin, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2011, 9 : 192 - 192
  • [47] Comparative cost-effectiveness for tildrakizumab and other targeted therapies for the treatment of moderate to severe plaque psoriasis in the United States
    Jia, Xiaoying
    Mendelsohn, Alan
    Zhang, Jingchuan
    Carrico, Justin
    Brodtkorb, Thor-Henrik
    Zhao, Yang
    Feldman, Steven
    Armstrong, April
    Wu, Jashin J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB80 - AB80
  • [48] COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB COMPARED TO CURRENT BIOLOGICS SEQUENCES FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN FRANCE
    Duteil, E.
    Cariou, C.
    Schmidt, A.
    Benjamin, K.
    Duco, J.
    VALUE IN HEALTH, 2016, 19 (07) : A589 - A589
  • [49] ASSESSMENT OF THE COST-EFFECTIVENESS OF SECUKINUMAB VERSUS RISANKIZUMAB FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN THE UK
    Moreno, S.
    Walsh, S.
    Khanna, P. J.
    Jain, M.
    Tanova-Yotova, N.
    VALUE IN HEALTH, 2022, 25 (12) : S89 - S89
  • [50] Interpretation of positive patient response to efalizumab for the treatment of moderate to severe plaque psoriasis
    Stone, S
    Papp, K
    Caro, I
    Bresnahan, B
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P157 - P157
12345